[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644849":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":10,"responsibleParty":22,"collaborators":10,"id":24,"slug":10,"hasResults":25,"nctId":26,"briefTitle":27,"officialTitle":28,"acronym":10,"eligibilityCriteria":29,"healthyVolunteers":25,"sex":30,"minAge":31,"maxAge":32,"enrollmentInfo":33,"targetDuration":10,"studyType":36,"phases":10,"briefSummary":37,"conditions":38,"keywords":40,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":50,"leadSponsor":52,"locationsCount":10},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"mCRPC Cohort",null,"Adult male patients with a recent diagnosis of mCRPC in PRECISION.",[13],{"name":14,"affiliation":14,"role":15},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[17,21],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},"CONTACT","+41613241111","novartis.email@novartis.com",{"name":14,"role":18,"phone":10,"phoneExt":10,"email":10},{"type":23,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100644849",false,"NCT07677254","A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer","Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Contemporary Patients With Metastatic Castration-Resistant Prostate Cancer in the PRECISION Data Platform","Inclusion criteria:\n\n* Diagnosis of mCRPC between 01 January 2021 and 31 December 2025.\n* Male sex at index, where index is the date of initial mCRPC diagnosis.\n* Age 18 years at index.\n\nExclusion criteria:\n\n• None","MALE","18 Years","115 Years",{"count":34,"type":35},17111,"ESTIMATED","OBSERVATIONAL","The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.",[39],"Prostatic Neoplasms, Castration-Resistant",[41,42,43],"Metastatic Castration-Resistant Prostate Cancer","Androgen Pathway Modulation-Resistant","APMR","NOT_YET_RECRUITING","2026-06-24",{"date":47,"type":48},"2026-06-30","ACTUAL",{"date":47,"type":35},{"date":51,"type":35},"2026-11-30",{"name":14,"class":6}]